Whilst the US BIOSECURE Act is not a blanket ban on Chinese outsourcing, it does create a new diligence and contracting challenge for UK life sciences companies.

It restricts US federal agencies, contractors and certain grant or loan recipients from procuring or using biotechnology equipment or services from designated ‘biotechnology companies of concern’ (BCCs).

In practice, however, the effect can travel far beyond the US. UK companies often sit within supply chains, collaborations or partnering arrangements that ultimately touch US federal funding or procurement.

Exposure to a China-linked CRO, CDMO or biotech supplier may become commercially relevant, even where the UK company itself receives no US government money.

A US customer, collaborator or other partner may ask whether any part of the supply chain depends on a supplier that is, or could become, a BCC. If the answer is yes, they may seek additional protections — from additional warranties to termination triggers.

For UK biotechs, the practical risk of relying on a supplier that is later designated as a BCC may not be felt in the short term.

For instance, it would not, by itself, block privately funded US clinical trials, FDA approval or certain types of US sales.